B. Metzler Seel. Sohn & Co. Ag Biogen Inc. Transaction History

B. Metzler Seel. Sohn & Co. Ag

$9.49 Billion
Q2 2024

A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Biogen Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 5,861 shares of BIIB stock, worth $1.02 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

5,861

Previous 5,720 2.47%

Holding current value

$1.02 Million

Previous $1.23 Million 10.14%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$190.52 - $236.72 $26,863 - $33,377	141 Added 2.47%	5,861 $1.36 Million
Q1 2024 May 15, 2024	SELL	$212.02 - $267.71 $154,562 - $195,160	-729 Reduced 11.3%	5,720 $1.23 Million
Q4 2023 Feb 13, 2024	SELL	$222.59 - $267.94 $489,475 - $589,200	-2,199 Reduced 25.43%	6,449 $1.67 Million
Q3 2023 Nov 13, 2023	BUY	$253.3 - $285.89 $496,468 - $560,344	1,960 Added 29.31%	8,648 $2.22 Million
Q2 2023 Aug 11, 2023	BUY	$275.25 - $318.06 $10,459 - $12,086	38 Added 0.57%	6,688 $1.91 Million
Q1 2023 May 10, 2023	SELL	$256.56 - $292.34 $278,624 - $317,481	-1,086 Reduced 14.04%	6,650 $1.85 Million
Q4 2022 Feb 13, 2023	BUY	$252.44 - $306.72 $201,194 - $244,455	797 Added 11.49%	7,736 $2.14 Million
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $722,105 - $995,718	-3,709 Reduced 34.83%	6,939 $1.85 Million
Q2 2022 Aug 12, 2022	SELL	$187.54 - $223.02 $24,567 - $29,215	-131 Reduced 1.22%	10,648 $2.17 Million
Q1 2022 May 10, 2022	BUY	$193.77 - $244.14 $113,161 - $142,577	584 Added 5.73%	10,779 $2.27 Million
Q4 2021 Feb 11, 2022	BUY	$223.92 - $287.77 $2.28 Million - $2.93 Million	10,195 New	10,195 $2.45 Million

Others Institutions Holding BIIB

# of Institutions

1,017

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of B. Metzler Seel. Sohn & Co. Ag, based on Form 13F filings with the SEC.

News

Stay updated on B. Metzler Seel. Sohn & Co. Ag with notifications on news.

Account

B. Metzler Seel. Sohn & Co. Ag Biogen Inc. Transaction History